DekaBank Deutsche Girozentrale Purchases 217 Shares of Exact Sciences Corporation $EXAS

DekaBank Deutsche Girozentrale boosted its stake in Exact Sciences Corporation (NASDAQ:EXAS) by 0.4% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 58,333 shares of the medical research company’s stock after purchasing an additional 217 shares during the period. DekaBank Deutsche Girozentrale’s holdings in Exact Sciences were worth $3,127,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Larson Financial Group LLC grew its holdings in Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after acquiring an additional 589 shares during the period. National Pension Service lifted its position in Exact Sciences by 75.1% in the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock valued at $29,000 after acquiring an additional 292 shares in the last quarter. SVB Wealth LLC bought a new position in Exact Sciences in the 1st quarter valued at about $30,000. Banque Cantonale Vaudoise bought a new position in shares of Exact Sciences during the 1st quarter worth approximately $34,000. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Exact Sciences during the 1st quarter worth approximately $34,000. 88.82% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on the stock. Evercore ISI lifted their price objective on shares of Exact Sciences from $64.00 to $68.00 and gave the company an “outperform” rating in a research note on Tuesday, October 7th. Wall Street Zen raised shares of Exact Sciences from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Piper Sandler boosted their price target on shares of Exact Sciences from $60.00 to $70.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research report on Saturday. Finally, Craig Hallum boosted their price objective on shares of Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $69.90.

Exact Sciences Trading Down 0.3%

Shares of NASDAQ EXAS opened at $64.64 on Friday. The firm’s 50 day moving average price is $54.24 and its 200-day moving average price is $51.86. The company has a market cap of $12.24 billion, a PE ratio of -11.90, a P/E/G ratio of 5.73 and a beta of 1.24. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $72.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89.

Exact Sciences (NASDAQ:EXAS) last issued its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.02) by $0.24. The firm had revenue of $811.09 million for the quarter, compared to the consensus estimate of $774.43 million. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The business’s revenue was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.09) earnings per share. On average, equities research analysts expect that Exact Sciences Corporation will post -0.58 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director James Edward Doyle sold 2,000 shares of the firm’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the completion of the transaction, the director directly owned 57,962 shares of the company’s stock, valued at approximately $3,477,720. This trade represents a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 1.20% of the company’s stock.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.